Bevacizumab treatment of patients with breast cancer is associated with differential expression and up-regulation of the thyrotroph embryonic factor, TEF.

The European Union ◽

Primary Tumors ◽

Bevacizumab Treatment ◽

Transcriptional Changes

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We integrated these findings with analysis of a separate microarray dataset studying transcriptional changes globally in the tumors of patients with bladder cancer following treatment with a regimen including bevacizumab (5). We report here the differential and increased expression of the TCDD inducible poly(ADP-ribose) polymerase, TIPARP, in the primary tumors of women treated with bevacizumab for breast cancer.

Bevacizumab treatment of patients with breast cancer is associated with differential expression and up-regulation of hepatic leukemia factor (HLF).

10.31219/osf.io/hwq3p ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

European Union ◽

Clinical Trials ◽

Microarray Data ◽

The United States ◽

The European Union ◽

Primary Tumors ◽

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We report here the differential and increased expression of the hepatic leukemia factor (5, 6) in the primary tumors of women treated with bevacizumab for breast cancer.

Bevacizumab treatment of patients with breast cancer is associated with induction of AP-1 transcription factor subunits.

10.31219/osf.io/hbn5m ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Transcription Factor ◽

Microarray Data ◽

The United States ◽

The European Union ◽

Primary Tumors ◽

Nuclear Factors ◽

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We report here the concomitant induction of AP1 transcription factor subunits JUN, FOS and FOSB in the primary tumors of women with breast cancer treated with bevacizumab, nuclear factors that trigger expression of a host of genes that support the proliferation and growth of cancer (5-13).

Bevacizumab treatment of patients with breast cancer is associated with differential expression and up-regulation of C10orf10.

10.31219/osf.io/w8yc5 ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Microarray Data ◽

Microarray Dataset ◽

The United States ◽

The European Union ◽

Primary Tumors ◽

Reading Frame ◽

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel; we integrated these findings with analysis of findings from a separate microarray dataset generated using bevacizumab administration in an experimental model of endometrial cancer (5). We report here the differential and increased expression of open reading frame 10 on chromosome 10, encoded by C10orf10 in the primary tumors of women treated with bevacizumab for breast cancer.

Bevacizumab treatment of patients with breast cancer is associated with induction of MYH11.

10.31219/osf.io/c2qvw ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

European Union ◽

Clinical Trials ◽

Microarray Data ◽

The United States ◽

The European Union ◽

Primary Tumors ◽

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We report here the induction of the myosin heavy chain MYH11 (5) in the primary tumors of women with breast cancer treated with bevacizumab.

Bevacizumab treatment of patients with breast cancer is associated with induction of SOX17.

10.31219/osf.io/d4u2h ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

European Union ◽

Clinical Trials ◽

Microarray Data ◽

The United States ◽

The European Union ◽

Primary Tumors ◽

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We report here the striking induction of the SRY-box morphogen transcription factor SOX17 (5-7) in the primary tumors of women with breast cancer treated with bevacizumab.

Bevacizumab treatment of patients with breast cancer results in induction of KLF2, KLF4, KLF6 and KLF9.

10.31219/osf.io/r46ey ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Microarray Data ◽

Ground State ◽

Embryonic Stem ◽

The United States ◽

The European Union ◽

Primary Tumors ◽

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We report here the striking induction of four separate KLF transcription factors in the primary tumors of women treated with bevacizumab: KLF2, KLF4, KLF6 and KLF9, two of which have established roles in the generation or maintenance of ground state pluripotency in embryonic stem cells (5, 6).

Bevacizumab treatment of patients with breast cancer is associated with induction of MYLK.

10.31219/osf.io/tcnpf ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Microarray Data ◽

Myosin Light Chain Kinase ◽

Myosin Light Chain ◽

The United States ◽

The European Union ◽

Primary Tumors ◽

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We report here the induction of the myosin light chain kinase MYLK (5) in the primary tumors of women with breast cancer treated with bevacizumab.

Bevacizumab treatment of patients with breast cancer is associated with differential expression and up-regulation of the leukemia inhibitory factor receptor (LIFR).

10.31219/osf.io/zb6dm ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Leukemia Inhibitory Factor ◽

Embryonic Stem ◽

The United States ◽

Inhibitory Factor ◽

The European Union ◽

Leukemia Inhibitory Factor Receptor ◽

Primary Tumors ◽

Chemotherapeutic Regimen

Bevacizumab (Avastin) is an approved treatment option by the European Medicines Agency (1) for more than a quarter billion women in the European Union, and despite having its indication withdrawn by the Food and Drug Administration in 2011 is still utilized in clinical trials in the United States (2, 3). We mined published microarray data (4) from the PROMIX trial to understand in an unbiased fashion genes most transcriptionally perturbed by bevacizumab administration and how this interacted with a standard anthracycline and taxane chemotherapeutic regimen, epirubicin and docetaxel. We report here the differential and increased expression of the leukemia inhibitory factor receptor, a gateway to a signaling pathway required for the pluripotency of embryonic stem cells (5, 6), in the primary tumors of women treated with bevacizumab for breast cancer.

DVL3 is over-expressed in the tumors of breast cancer patients treated with trastuzumab.

10.31219/osf.io/qkh84 ◽

2020 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

The United States ◽

Breast Cancer Patients ◽

Gene Encoding ◽

Significant Differential Expression ◽

Primary Tumors ◽

Unbiased Manner

Trastuzumab (Herceptin) is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) (1) utilized for the treatment of adjuvant and metastatic breast cancer (2) in the United States and worldwide. We mined published and public microarray and gene expression data (3, 4) to discover in an unbiased manner the most striking transcriptional features of trastuzumab treatment. We identified significant differential expression of the gene encoding the Wnt pathway molecule dishevelled-3, DVL3 (5-7), in the primary tumors of breast cancer patients treated with trastuzumab. DVL3 expression in primary tumors of the breast in patients treated with trastuzumab was significantly higher than in patients not treated with trastuzumab.